Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1679108

registered interest
date	19/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Cancers: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much funding her Department has provided for research that has led to clinical trials for (a) paediatric cancer, (b) neuroblastoma and (c) other rare cancers in each of the last five years.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	7496
answer	answer is ministerial correction date of answer 08/01/2024 answer text <p>The information requested is shown in the attached table.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 08/01/2024 10:41:08 answering member 4044 label Biography information for Andrew Stephenson attachment 1 file name FORMATTED TABLE FOR MINISTERIAL CLEARANCE PQ 7496. ATTATCHMENT research led to clinical trials for paediatric cancer neuroblastoma (1).docx title Attachment
tabling member	1383 label Biography information for Mark Tami

1670001

registered interest
date	14/11/2023
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Poverty: North Wales
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Work and Pensions, what recent estimate he has made of the number of (a) adults and (b) children living in destitution in each constituency in North Wales.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	1820
answer	answer is ministerial correction date of answer 21/11/2023 answer text <p>No assessment has been made of the number of adults and children living in destitution in North Wales.</p><p> </p><p>This government is committed to reducing poverty, including child poverty, and supporting low-income families and has overseen significant falls in absolute poverty since 2009/10.</p><p> </p><p>In 2021/22 there were 1.7 million fewer people in absolute poverty after housing costs than in 2009/10, including 400,000 fewer children, 1 million fewer working age adults and 200,000 fewer pensioners. Rates of absolute poverty after housing costs for individuals in families in receipt of Universal Credit have also fallen by 12ppt since 2019/20.</p><p> </p><p>In Wales, in the three years to 2021/22 there were an average of 500,000 individuals (or 16%) in absolute poverty after housing costs, including 100,000 children. This is 200,000 fewer than in 2009/10, or a 6 percentage point decrease.</p><p> </p><p>Poverty statistics for all individuals are not available at the constituency level. The numbers of children living in low income families before housing costs by constituency are published in the Children in Low Income Families Publication, available <a href="https://www.gov.uk/government/collections/children-in-low-income-families-local-area-statistics" target="_blank">here.</a></p><p> </p><p>The UK Government understands the pressures people are facing with the cost of living. We are providing total support of over £94bn over 2022-23 and 2023-24 to help households and individuals with the rising bills.</p><p> </p><p>We are providing an additional £1 billion of funding, including Barnett impact for the devolved administrations, to enable a further extension to the Household Support Fund (HSF) in England over the 2023/24 financial year. As with all government spending in England, the HSF has led to consequential increases in Barnett funding, which the DAs spend at their discretion. As a result of the Household Support Fund extension, Wales has been allocated £50m.</p><p> </p><p>With almost one million job vacancies across the UK, our focus remains firmly on supporting people, including parents, to move into and progress in work. This approach is based on clear evidence about the importance of employment, particularly where it is full-time, in substantially reducing the risks of poverty. The latest statistics show that in 2021/22 children living in workless households were 5 times more likely to be in absolute poverty, after housing costs, than those where all adults work.</p><p>To help people into work, our core Jobcentre offer provides a range of options, including face-to-face time with work coaches and interview assistance. In addition, there is specific support targeted towards young people, people aged 50 plus and job seekers with disabilities or health issues.</p><p> </p><p>To support those who are in work, from 1 April 2023, the National Living Wage (NLW) increased by 9.7% to £10.42 an hour for workers aged 23 and over - the largest ever cash increase for the NLW. In addition, the voluntary in-work progression offer started to roll-out in April 2022. It is now available in all Jobcentres across Great Britain. We estimate that around 1.4m low-paid benefit claimants will be eligible for support to progress into higher-paid work.</p><p> </p><p>To further support parents into work, on 28th June 2023, the maximum monthly amounts that a parent can be reimbursed for their childcare increased by 47%, from £646.35 for one child and £1,108.04 for two or more children to £950.92 and £1,630.15 respectively. Importantly, we can now also provide even more help with upfront childcare costs when parents move into work or increase their hours. This means that a parent who needs this additional financial help can now be provided with funding towards both their first and second set of costs (or increased costs), upfront, thereby easing them into the UC childcare costs cycle.</p> answering member constituency Mid Sussex answering member printed Mims Davies question first answered 21/11/2023 17:02:12 answering member 4513 label Biography information for Mims Davies
tabling member	1383 label Biography information for Mark Tami

1669430

registered interest
date	13/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Graft versus Host Disease: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to address regional disparities in access to newer treatments for Graft-versus-host disease.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	1456
answer	answer is ministerial correction date of answer 22/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether new medicines represent a clinically- and cost-effective use of NHS resources. The NHS in England is legally required to make funding available in line with NICE’s recommendations within 90 days of a NICE decision, ensuring consistent access for all NHS patients in England to NICE recommended treatments.</p><p>NICE works closely with NHS England and pharmaceutical companies throughout the guidance development process to ensure that companies can put forward as strong a value proposition as possible. NICE can recommend most new medicines for use in the NHS in England. Health is a devolved matter and decisions on access to medicines in Scotland, Northern Ireland, and Wales are a matter for the devolved administrations.</p><p>NICE is currently evaluating the medicine belumosudil for treating chronic graft versus host disease after two or more lines of systemic therapy. NICE’s draft guidance does not recommend belumosudil but is subject to a public consultation and is not final guidance. NICE’s committee will carefully consider all evidence as well as comments received during the consultation in developing its final guidance.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 1459 question first answered 22/11/2023 15:50:10 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1383 label Biography information for Mark Tami

1669431

registered interest
date	13/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the adequacy apheresis capacity; and what plans her Department has to increase that capacity.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	1457
answer	answer is ministerial correction date of answer 23/11/2023 answer text <p>The NHS England Specialised Commissioning, via the Bone Marrow Transplant Clinical Reference Group (CRG), is undertaking an assessment of the available apheresis capacity across England, working with NHS Blood and Transplant. The first phase of this assessment is complete and the CRG will define the next phase of this assessment at its meeting in November.</p><p>NHS Blood and Transplant is the largest provider of apheresis services and has been increasing capacity significantly over a number of years, averaging an increase of about 10% per annum. There are a number of projects expected in the next 12 months to both increase nursing capacity and the physical space in which apheresis occurs.</p><p>Horizon scanning within the advanced therapy area suggests that a significant increase in cell collection will be required within the next three to five years. The MedTech Funding Mandate for Spectra Optia in sickle cell disease has assisted in funding the expansion of services. NHS England is working in partnership with the Health Innovation Network to deliver the requirements of the MedTech Funding Mandate Policy which mandates the delivery of the Spectra Optia Apheresis System for the automation of red cell exchange for sickle cell patients. Funding has been provided to increase access to this technology across the country.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 23/11/2023 13:34:12 answering member 4117 label Biography information for Andrea Leadsom
tabling member	1383 label Biography information for Mark Tami

1669432

registered interest
date	13/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help ensure that (a) new clinical trials have the support they need to recruit patients and (b) patients are made aware of clinical trials as a potential way to access new medicines.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	1458
answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>The Department funds research through the National Institute for Health and Care Research (NIHR). NIHR invests in expertise, specialist facilities, a research delivery workforce and support services to support recruitment to clinical trials. The NIHR Clinical Research Facilities support the delivery of early phase trials and the NIHR Clinical Research Network (CRN) and Patient Recruitment Centres support delivery and participation in later phase clinical trials.</p><p>The NIHR also provides the online platform 'Be Part of Research' which allow users to search for and register interest in clinical trials, matching people to trials of relevance to them.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/11/2023 17:23:48 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1383 label Biography information for Mark Tami

1669433

registered interest
date	13/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Graft versus Host Disease: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help ensure that (a) NICE, (b) NHS England and (c) he pharmaceutical industry work together to increase patient access to new therapies for Graft-versus-host disease.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	1459
answer	answer is ministerial correction date of answer 22/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether new medicines represent a clinically- and cost-effective use of NHS resources. The NHS in England is legally required to make funding available in line with NICE’s recommendations within 90 days of a NICE decision, ensuring consistent access for all NHS patients in England to NICE recommended treatments.</p><p>NICE works closely with NHS England and pharmaceutical companies throughout the guidance development process to ensure that companies can put forward as strong a value proposition as possible. NICE can recommend most new medicines for use in the NHS in England. Health is a devolved matter and decisions on access to medicines in Scotland, Northern Ireland, and Wales are a matter for the devolved administrations.</p><p>NICE is currently evaluating the medicine belumosudil for treating chronic graft versus host disease after two or more lines of systemic therapy. NICE’s draft guidance does not recommend belumosudil but is subject to a public consultation and is not final guidance. NICE’s committee will carefully consider all evidence as well as comments received during the consultation in developing its final guidance.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 1456 question first answered 22/11/2023 15:50:10 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1383 label Biography information for Mark Tami

1669434

registered interest
date	13/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Graft versus Host Disease: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to support (a) IMPACT, (b) AGAVE and (c) other clinical trials for new Graft-versus-host disease treatments.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	1460
answer	answer is ministerial correction date of answer 22/11/2023 answer text <p>NHS Blood and Transplant (NHSBT) have received funding from the Department to set up a process for manufacturing and supplying mesenchymal stromal cells for the treatment of Graft-versus-host disease (GvHD). This process has been set up and the first batches of cells will be available for supply from NHSBT in 2024. These will be issued upon request from hospitals under the Specials program but is not routinely commissioned.</p><p>NHSBT funded the IMPACT clinical trials network and subsequently Advancing Clinical Trials Ltd (ACT). The network is currently running two trials in the area of GvHD. NHSBT with the National Institute for Health and Care Research (NIHR) fund research into transplantation and cellular therapy via the Blood and Transplant Research Unit based in Oxford. While at an early stage, some of the projects leading from this aim to reduce and/or treat GvHD. The NIHR has further supported the delivery of the AGAVE clinical trial via the NIHR infrastructure.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/11/2023 15:37:45 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1383 label Biography information for Mark Tami

1666223

registered interest
date	19/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with representatives of young people on the development of the Major Conditions Strategy.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	203446
answer	answer is ministerial correction date of answer 24/10/2023 answer text <p>The Department is engaging with several stakeholders in the development of the Major Conditions Strategy including organisations that represent babies, children and young people.</p> answering member constituency Colchester answering member printed Will Quince question first answered 24/10/2023 15:19:54 answering member 4423 label Biography information for Will Quince
tabling member	1383 label Biography information for Mark Tami

1666224

registered interest
date	19/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Commercial Clinical Trials in the UK Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he plans to take to ensure that implementation of the recommendations made in the Lord O’Shaughnessy review of commercial clinical trials in the UK takes into account the particular needs of (a) teenagers and (b) young adults with cancer.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	203447
answer	answer is ministerial correction date of answer 23/10/2023 answer text <p>The Government will publish a full response to the Lord O’Shaughnessy independent review into commercial clinical trials in autumn 2023. The response will include an update on progress and implementation of the initial five headline commitments and foundational actions that the Government made in May 2023.</p> answering member constituency Colchester answering member printed Will Quince question first answered 23/10/2023 14:25:02 answering member 4423 label Biography information for Will Quince
tabling member	1383 label Biography information for Mark Tami

1663467

registered interest
date	13/10/2023
answering body	Department for Levelling Up, Housing and Communities
answering dept id	211
answering dept short name	Levelling Up, Housing and Communities
answering dept sort name	Levelling Up, Housing and Communities
hansard heading	Land: Registration
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Levelling Up, Housing and Communities, what recent steps he has taken to help ensure HM Land Registry completes the registration of new titles where a previously registered plot has been divided.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	201321
answer	answer is ministerial correction date of answer 23/10/2023 answer text <p>The department does not hold the information in the format requested to answer question 201322, and it could only be provided at disproportionate cost. HMLR publishes information each month about its latest processing times on GOV.UK <a href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fguidance%2Fhm-land-registry-processing-times&amp;data=05%7C01%7CParliamentary%40levellingup.gov.uk%7C772d05c0257e4a134daa08dbd3aeafed%7Cbf3468109c7d43dea87224a2ef3995a8%7C0%7C0%7C638336519453768940%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=FwIbaPVO7VswzDGr5xNRNDLMN57MRoUM0ak1%2BVaW9GA%3D&amp;reserved=0" target="_blank">here</a></p><p><br>Applications to HM Land Registry (HMLR) are protected with priority from their date of receipt. Provided they contain the information required for registration, they are guaranteed to be processed. I refer the Hon Member to the answer I gave to Question <a href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fquestions-statements.parliament.uk%2Fwritten-questions%2Fdetail%2F2023-06-06%2F187953&amp;data=05%7C01%7CParliamentary%40levellingup.gov.uk%7C772d05c0257e4a134daa08dbd3aeafed%7Cbf3468109c7d43dea87224a2ef3995a8%7C0%7C0%7C638336519453768940%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=7T8HqNiB11bCuZpSedMLk4%2BmEmkSD1s2ucWr4%2BeGOTM%3D&amp;reserved=0" target="_blank">UIN 187953</a> on 14 June 2023 for information about the steps HMLR is taking to improve its speed of service.</p><p> </p><p> </p> answering member constituency Redditch answering member printed Rachel Maclean grouped question UIN 201322 question first answered 23/10/2023 10:18:02 answering member 4668 label Biography information for Rachel Maclean
tabling member	1383 label Biography information for Mark Tami